Trial Profile
A Phase 1-2 Study of the Combination of Olaparib and Tremelimumab, in BRCA1 and BRCA2 Mutation Carriers With Recurrent Ovarian Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 06 Oct 2022
Price :
$35
*
At a glance
- Drugs Olaparib (Primary) ; Tremelimumab (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 12 Jan 2021 Planned End Date changed from 1 Feb 2022 to 15 Jul 2027.
- 12 Jan 2021 Planned primary completion date changed from 1 Feb 2020 to 15 Jul 2022.
- 12 Jan 2021 Status changed from recruiting to active, no longer recruiting.